Testosterone Restoration, the Gut Microbiome, and Systems Outcomes in Men and Women
Testosterone restoration therapy (TRT) is increasingly used in men and, when clinically indicated, in women. Emerging evidence shows bidirectional crosstalk between sex steroids and the gut microbiome, with implications for metabolic, neuropsychiatric, and inflammatory outcomes. This brief synthesises current data to guide clinicians on integrating gut assessment and modulation with TRT.
- sex hormones shape microbial composition and function, and microbes metabolise/steward steroid bioavailability;
- low testosterone states associate with dysbiosis and inflammatory taxa;
- sex-dimorphic microbiome–disease patterns extend to the gut–brain axis; and
- microbiota-directed adjuncts (e.g., probiotics/synbiotics) show early signals of benefit in hyperandrogenic states such as PCOS.
1) Physiological Background
Sex steroids (testosterone, estradiol, progesterone) modulate immune tone, musculoskeletal anabolism, neurocognition, and cardio-metabolic risk across the lifespan…
2) Sexual Dimorphism & Disease Patterns
Across preclinical and human data, sex differences in obesity and metabolic disease are partly explained…
Gut–brain axis:
Large cohort data show that associations between specific gut taxa and psychological symptom severity…
3) Low Testosterone & Dysbiosis
Observational clinical data in men with type 2 diabetes demonstrate that low serum testosterone associates with reduced microbial diversity…
4) Women’s Health: Hyperandrogenism & Microbiota
In PCOS, multiple systematic reviews/meta-analyses indicate probiotics/synbiotics can improve glycaemic indices…
5) Clinical Implications for TRT at Levitas
- Persistent fatigue, brain fog, visceral adiposity or glycaemic instability despite dose-appropriate TRT
- GI symptoms, recurrent antibiotics, PPI use
- Raised CRP, ferritin, ALT, or metabolic syndrome
Integrated pathway (Levitas Gut Health × Hormone for Life):
Baseline profiling, foundations, TRT initiation, gut-directed adjuncts, re-evaluation.
| Parameter | Baseline | 8–12 Weeks | 24 Weeks | Target |
|---|---|---|---|---|
| Testosterone | ✓ | ✓ | ✓ | 20–30 nmol/L |
| LH & FSH | ✓ | ✓ | ✓ | Mid-range |
| E2 | ✓ | ✓ | ✓ | <150 pmol/L |
| Microbiome | ✓ | Optional | ✓ | Diversity Maintained |
6) Safety & Governance
- Follow established TRT safety monitoring
- Screen secondary causes of hypogonadism
- Microbiome therapeutics are adjuncts
7) Research Priorities (Levitas Academy)
- Prospective microbiome signatures in TRT
- TRT ± synbiotic RCT in metabolic syndrome
- PCOS microbiome-informed phenotypes
- Neurobehavioral biomarkers under TRT
For clinicians across Levitas Clinics: Pair TRT with gut assessment, use microbiome adjuncts where dysbiosis is present, and track whole-body outcomes.
